2D Image Software Eliminates Need for a 2D Mammogram in a 2D/3D Tomosynthesis Exam

Hologic, Inc. (Bedford, MA, USA), a developer, manufacturer, and supplier of diagnostic products, medical imaging systems, and surgical products focused on serving the healthcare needs of women, announced the commercial release of its C-View software. The software is approved for sale throughout the European Economic Area and in other countries recognizing the CE marking.

For users of Hologic’s 2D plus 3D tomosynthesis breast cancer screening system, C-View software creates a 2D image from a single tomosynthesis scan and eliminates the need for the acquisition of additional 2D exposures.

Dr. Stephen Rose, a board-certified radiologist with Houston Breast Imaging (TX, USA), one of the first US radiologists to adopt breast tomosynthesis, stated “Hologic’s synthesized 2D image reconstruction algorithm is very impressive. C-View provides the information contained in a conventional 2D mammogram without the need for additional exposures while maintaining the superior clinical performance of Hologic’s combo-mode [2D plus 3D] imaging.”

Hologic presented the new algorithm along with the company’s Selenia Dimensions breast tomosynthesis system at the scientific assembly and annual meeting of the Radiological Society of North America (RSNA), held in Chicago, IL, USA, November 26-December 2, 2010.

Hologic is a global market leader in breast tomosynthesis (3D mammography) with its Selenia Dimensions platform. In Hologic’s clinical studies, radiologists reading in combo-mode (2D plus 3D) compared to 2D mammography alone demonstrated superior clinical performance in ruling out breast cancer without recalling the patient for further study and the proportion of mammograms with cancer which were correctly diagnosed.

Hologic, Inc.’s core business units are focused on breast health, diagnostics, gyn surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging (MRI), radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini-C-arm for extremity imaging, and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

Related Links:
Hologic